Literature DB >> 29033267

Palliative care in interstitial lung disease: living well.

Michael Kreuter1, Elisabeth Bendstrup2, Anne-Marie Russell3, Sabrina Bajwah4, Kathleen Lindell5, Yochai Adir6, Crystal E Brown7, Greg Calligaro8, Nicola Cassidy9, Tamera J Corte10, Klaus Geissler11, Azza Adel Hassan12, Kerri A Johannson13, Ronaldo Kairalla14, Martin Kolb15, Yasuhiro Kondoh16, Sylvia Quadrelli17, Jeff Swigris18, Zarir Udwadia19, Athol Wells20, Marlies Wijsenbeek21.   

Abstract

Progressive fibrotic interstitial lung diseases (ILDs) are characterised by major reductions in quality of life and survival and have similarities to certain malignancies. However, palliative care expertise is conspicuously inaccessible to many patients with ILD. Unmet patient and caregiver needs include effective pharmacological and psychosocial interventions to improve quality of life throughout the disease course, sensitive advanced care planning, and timely patient-centred end-of-life care. The incorrect perception that palliative care is synonymous with end-of-life care, with no role earlier in the course of ILD, has created a culture of neglect. Interventions that aim to improve life expectancy are often prioritised without rigorous assessment of the individual's health and psychosocial needs, thereby inadvertently reducing quality of life. As in malignant disorders, radical interventions to slow disease progression and palliative measures to improve quality of life should both be prioritised. Efficient patient-centred models of palliative care must be validated, taking into account religious and cultural differences, as well as variability of resources. Effective implementation of palliative care for ILD will require multidisciplinary participation from clinicians, specialist nurses, psychologists, social workers, and, in some countries, non-governmental faith and community-based organisations with access to palliative care expertise.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29033267     DOI: 10.1016/S2213-2600(17)30383-1

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


  47 in total

1.  The Diagnosis and Treatment of Pulmonary Fibrosis.

Authors:  Michael Kreuter; Ulf Müller Ladner; Ulrich Costabel; Danny Jonigk; Claus Peter Heussel
Journal:  Dtsch Arztebl Int       Date:  2021-03-05       Impact factor: 5.594

Review 2.  Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease.

Authors:  Wim A Wuyts; Marlies Wijsenbeek; Benjamin Bondue; Demosthenes Bouros; Paul Bresser; Carlos Robalo Cordeiro; Ole Hilberg; Jesper Magnusson; Effrosyni D Manali; António Morais; Spyridon Papiris; Saher Shaker; Marcel Veltkamp; Elisabeth Bendstrup
Journal:  Respiration       Date:  2019-12-12       Impact factor: 3.580

3.  Nonpharmacological therapies for interstitial lung disease.

Authors:  Kathleen Oare Lindell
Journal:  Curr Pulmonol Rep       Date:  2018-10-18

Review 4.  Acute exacerbation of interstitial lung disease associated with rheumatic disease.

Authors:  Fabrizio Luppi; Marco Sebastiani; Carlo Salvarani; Elisabeth Bendstrup; Andreina Manfredi
Journal:  Nat Rev Rheumatol       Date:  2021-12-07       Impact factor: 20.543

5.  Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.

Authors:  David Singer; Lindsay G S Bengtson; Craig S Conoscenti; Marianne Laouri; Sharash S Shetty; Amy J Anderson; Kevin K Brown
Journal:  Ann Am Thorac Soc       Date:  2022-07

6.  Randomised clinical trial of an early palliative care intervention (SUPPORT) for patients with idiopathic pulmonary fibrosis (IPF) and their caregivers: protocol and key design considerations.

Authors:  Kathleen Oare Lindell; Mehdi Nouraie; Melinda J Klesen; Sara Klein; Kevin F Gibson; Daniel J Kass; Margaret Quinn Rosenzweig
Journal:  BMJ Open Respir Res       Date:  2018-02-19

Review 7.  The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease.

Authors:  Anna-Maria Hoffmann-Vold; Yannick Allanore; Elisabeth Bendstrup; Cosimo Bruni; Oliver Distler; Toby M Maher; Marlies Wijsenbeek; Michael Kreuter
Journal:  Respir Res       Date:  2020-07-23

8.  Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease - a randomised placebo-controlled trial.

Authors:  Sissel Kronborg-White; Charlotte Uggerhøj Andersen; Charlotte Kohberg; Ole Hilberg; Elisabeth Bendstrup
Journal:  Respir Res       Date:  2020-07-23

9.  Management and support of patients with fibrosing interstitial lung diseases.

Authors:  Tyonn Barbera; Lesley Davila; Nina M Patel
Journal:  Nurse Pract       Date:  2021-07-01

10.  The Value of the Surprise Question to Predict One-Year Mortality in Idiopathic Pulmonary Fibrosis: A Prospective Cohort Study.

Authors:  Catharina C Moor; Nelleke C Tak van Jaarsveld; Catherine Owusuaa; Jelle R Miedema; Sara Baart; Carin C D van der Rijt; Marlies S Wijsenbeek
Journal:  Respiration       Date:  2021-05-27       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.